
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/822081/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An epigenome-wide association study of total serum immunoglobulin E concentration. Nature, 2015, 520, 670-674.	27.8	193
2	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	27.6	189
3	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology, 2011, 50, 762-767.	1.9	188
4	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
5	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychological Medicine, 2020, 50, 1368-1380.	4.5	175
6	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis and Rheumatology, 2017, 69, 1067-1077.	5.6	139
7	An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies. Genome Biology, 2016, 17, 84.	8.8	137
8	Healthâ€related quality of life in systemic sclerosis: A systematic review. Arthritis and Rheumatism, 2009, 61, 1112-1120.	6.7	129
9	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care and Research, 2012, 64, 519-524.	3.4	117
10	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism, 2014, 43, 666-672.	3.4	115
11	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.9	107
12	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	1.9	104
13	Polyautoimmunity and familial autoimmunity in systemic sclerosis. Journal of Autoimmunity, 2008, 31, 156-159.	6.5	101
14	Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. Environmental Research, 2016, 146, 85-91.	7.5	94
15	Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care and Research, 2015, 67, 1237-1245.	3.4	88
16	Psychological health and wellâ€being in systemic sclerosis: State of the science and consensus research agenda. Arthritis Care and Research, 2010, 62, 1181-1189.	3.4	79
17	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
18	Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatology International, 2012, 32, 645-653.	3.0	76

#	Article	IF	CITATIONS
19	Cigarette smoking in patients with systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 230-238.	6.7	74
20	The validity of administrative data to identify hip fractures is high—a systematic review. Journal of Clinical Epidemiology, 2013, 66, 278-285.	5.0	71
21	Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open, 2017, 7, e014719.	1.9	71
22	Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis and Rheumatism, 2008, 59, 270-278.	6.7	68
23	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics, 2020, 89, 25-37.	8.8	67
24	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. Rheumatology, 2014, 53, 1386-1394.	1.9	65
25	Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic Conditions. Journal of Rheumatology, 2009, 36, 768-772.	2.0	64
26	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. Journal of Rheumatology, 2014, 41, 2179-2185.	2.0	63
27	Work Disability in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 2481-2486.	2.0	61
28	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	3.4	60
29	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. Arthritis Care and Research, 2015, 67, 582-587.	3.4	60
30	Update on Indices of Disease Activity in Systemic Sclerosis. Seminars in Arthritis and Rheumatism, 2007, 37, 93-98.	3.4	57
31	Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 787-794.	2.0	54
32	Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environmental Research, 2015, 140, 474-478.	7.5	54
33	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	1.9	53
34	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. British Journal of Psychiatry, 2018, 212, 377-385.	2.8	53
35	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. European Respiratory Review, 2018, 27, 170102.	7.1	53
36	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53

#	Article	IF	CITATIONS
37	Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. Rheumatology, 2016, 55, 2148-2155.	1.9	52
38	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	1.9	51
39	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.9	50
40	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Research and Therapy, 2020, 22, 5.	3.5	48
41	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis and Rheumatism, 2008, 59, 279-284.	6.7	47
42	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. Journal of Rheumatology, 2020, 47, 166-175.	2.0	47
43	Systemic Sclerosis. Medicine (United States), 2010, 89, 159-165.	1.0	45
44	Diagnostic criteria of systemic sclerosis. Journal of Autoimmunity, 2014, 48-49, 38-41.	6.5	44
45	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmunity Reviews, 2020, 19, 102595.	5.8	44
46	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
47	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 120, 104-111.	0.4	40
48	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology, 2019, 58, 683-691.	1.9	38
49	Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatism, 2017, 46, 488-508.	3.4	37
50	Adverse events associated with immune checkpoint inhibitor treatment for cancer. Cmaj, 2019, 191, E40-E46.	2.0	36
51	Time to diagnosis in systemic sclerosis: Is sex a factor?. Arthritis and Rheumatism, 2009, 61, 274-278.	6.7	35
52	The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. Journal of Rheumatology, 2003, 30, 2385-91.	2.0	35
53	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology, 2019, 58, 636-644.	1.9	34
54	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.7	33

#	Article	IF	CITATIONS
55	FRI0258â€CUMULATIVE INCIDENCE, SURVIVAL AND PREDICTORS OF PULMONARY HYPERTENSION IN SYSTEMI SCLEROSIS SUBSETS: PAH IS NOT INCREASED IN LIMITED VS DIFFUSE PATIENTS BY ADJUSTED COMPETING RISK ANALYSIS. Annals of the Rheumatic Diseases, 2020, 79, 713-713.	IC 0.9	33
56	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2307-2312.	2.0	32
57	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. Journal of Pain and Symptom Management, 2016, 52, 43-53.	1.2	32
58	Towards developing criteria for scleroderma renal crisis: A scoping review. Autoimmunity Reviews, 2017, 16, 407-415.	5.8	32
59	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	3.4	31
60	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunology, Immunotherapy, 2021, 70, 2197-2207.	4.2	31
61	Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care and Research, 2010, 62, 805-810.	3.4	30
62	Statins and Risk of Rheumatoid Arthritis: A Nested Case–Control Study. Arthritis and Rheumatology, 2016, 68, 2603-2611.	5.6	30
63	Industrial air emissions, and proximity to major industrial emitters, are associated with anti-citrullinated protein antibodies. Environmental Research, 2017, 157, 60-63.	7.5	30
64	Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. Journal of Rheumatology, 2020, 47, 770-778.	2.0	30
65	Thinking outside the box—The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in Arthritis and Rheumatism, 2015, 45, 184-189.	3.4	29
66	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 2015, 48, 542-551.	2.6	29
67	Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS ONE, 2016, 11, e0160753.	2.5	29
68	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 338-344.	3.4	28
69	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. PLoS ONE, 2019, 14, e0216075.	2.5	25
70	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 2020, 19, 102583.	5.8	25
71	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. Arthritis Care and Research, 2016, 68, 673-680.	3.4	24
72	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 2015, 33, S131-5.	0.8	24

#	Article	IF	CITATIONS
73	Rheumatoid arthritis prevalence in Quebec. BMC Research Notes, 2014, 7, 937.	1.4	23
74	Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. BMC Rheumatology, 2018, 2, 18.	1.6	23
75	Long-term exposure to a mixture of industrial SO2, NO2, and PM2.5 and anti-citrullinated protein antibody positivity. Environmental Health, 2020, 19, 86.	4.0	23
76	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open, 2020, 6, e001357.	3.8	23
77	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. Journal of Rheumatology, 2014, 41, 1334-1343.	2.0	22
78	Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. PLoS ONE, 2016, 11, e0152419.	2.5	22
79	funtooNorm: an R package for normalization of DNA methylation data when there are multiple cell or tissue types. Bioinformatics, 2016, 32, 593-595.	4.1	22
80	Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis. BMC Medical Genomics, 2019, 12, 144.	1.5	22
81	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101707.	3.3	22
82	Hypocomplementemia in systemic sclerosisclinical and serological correlations. Journal of Rheumatology, 2007, 34, 2218-23.	2.0	21
83	Longitudinal Study of Renal Function in Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 1829-1834.	2.0	20
84	The Canadian Systemic Sclerosis Oral Health Study II: the relationship between oral and global health-related quality of life in systemic sclerosis. Rheumatology, 2015, 54, 692-696.	1.9	20
85	Investigating associations between anti-nuclear antibody positivity and combined long-term exposures to NO2, O3, and PM2.5 using a Bayesian kernel machine regression approach. Environment International, 2020, 136, 105472.	10.0	20
86	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. Autoimmunity Reviews, 2018, 17, 267-275.	5.8	19
87	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	3.5	18
88	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. Disability and Rehabilitation, 2018, 40, 1997-2003.	1.8	17
89	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmunity Reviews, 2021, 20, 102851.	5.8	17
90	Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1226-1229.	2.0	16

#	Article	IF	CITATIONS
91	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. Arthritis Care and Research, 2017, 69, 124-132.	3.4	16
92	Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. Depression and Anxiety, 2019, 36, 82-92.	4.1	16
93	Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant—a systematic review. Rheumatology, 2020, 59, 779-789.	1.9	16
94	Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology, 2022, 61, 1148-1157.	1.9	16
95	Comparative effectiveness research with administrative health data in rheumatoid arthritis. Nature Reviews Rheumatology, 2016, 12, 358-366.	8.0	15
96	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatology, 2019, 58, 1393-1399.	1.9	15
97	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. Clinical Rheumatology, 2020, 39, 2931-2941.	2.2	15
98	Scleroderma renal crisis. Presse Medicale, 2021, 50, 104063.	1.9	15
99	Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology, 2018, 29, 904-912.	2.7	14
100	Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. Clinical Epigenetics, 2019, 11, 110.	4.1	14
101	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. PLoS ONE, 2014, 9, e91979.	2.5	13
102	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology, 2016, 56, kew441.	1.9	13
103	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
104	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2019, 48, 1053-1058.	3.4	13
105	Mortality and morbidity in scleroderma renal crisis: A systematic literature review. Journal of Scleroderma and Related Disorders, 2021, 6, 21-36.	1.7	13
106	Effectiveness of Allopurinol in Reducing Mortality: Timeâ€Related Biases in Observational Studies. Arthritis and Rheumatology, 2021, 73, 1749-1757.	5.6	13
107	Modeling smoking in systemic sclerosis: A comparison of different statistical approaches. Arthritis Care and Research, 2011, 63, 570-578.	3.4	12
108	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 2016, 43, 1510-1518.	2.0	12

#	Article	IF	CITATIONS
109	Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. Seminars in Arthritis and Rheumatism, 2019, 49, 366-372.	3.4	12
110	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 166-175.	2.0	12
111	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology, 2020, 59, 1108-1117.	1.9	12
112	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. Disability and Rehabilitation, 2021, 43, 3339-3346.	1.8	12
113	The Effect of <scp>Antiâ€Scl</scp> â€70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. ACR Open Rheumatology, 2022, 4, 345-351.	2.1	12
114	Reasons for non-participation in scleroderma support groups. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 56-62.	0.8	12
115	Subsets in systemic sclerosis: one size does not fit all. Journal of Scleroderma and Related Disorders, 2016, 1, 298-306.	1.7	11
116	Development and Validation of the Body Concealment Scale for Scleroderma. Arthritis Care and Research, 2016, 68, 1158-1165.	3.4	11
117	Designing Discrete Choice Experiments Using a Patient-Oriented Approach. Patient, 2021, 14, 389-397.	2.7	11
118	Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology, 2022, 61, 2905-2914.	1.9	11
119	<i>Helicobacter pylori</i> serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncolmmunology, 2022, 11, .	4.6	11
120	Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?. Seminars in Arthritis and Rheumatism, 2021, 51, 211-218.	3.4	10
121	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Healthâ€Related Quality of Life. Arthritis and Rheumatology, 2021, 73, 305-314.	5.6	10
122	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes—Methodology and Preliminary Results. International Journal of Rheumatology, 2010, 2010, 1-7.	1.6	9
123	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. Clinical Rheumatology, 2017, 36, 373-379.	2.2	9
124	Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial. BMJ Open, 2019, 9, e029935.	1.9	9
125	Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. Journal of Rheumatology, 2021, 48, 16-24.	2.0	9
126	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. PLoS ONE, 2014, 9, e102897.	2.5	9

#	Article	IF	CITATIONS
127	Scleroderma renal crisis. Current Opinion in Rheumatology, 2015, 27, 549-554.	4.3	8
128	Understanding coping strategies among people living with scleroderma: a focus group study. Disability and Rehabilitation, 2018, 40, 3012-3021.	1.8	8
129	Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. Journal of Scleroderma and Related Disorders, 2018, 3, 221-227.	1.7	8
130	Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program. Trials, 2019, 20, 717.	1.6	8
131	Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. Rheumatology, 2021, 60, 5257-5270.	1.9	8
132	Challenges of Perceived <scp>Selfâ€Management</scp> in Lupus. Arthritis Care and Research, 2022, 74, 1113-1121.	3.4	8
133	Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. Clinical and Experimental Rheumatology, 2015, 33, S179-81.	0.8	8
134	Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. Clinical Rheumatology, 2013, 32, 1467-1474.	2.2	7
135	Immune-Mediated Necrotizing Myopathy and Dietary Sources of Statins. Annals of Internal Medicine, 2018, 168, 893.	3.9	7
136	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol. Journal of Scleroderma and Related Disorders, 2018, 3, 91-97.	1.7	7
137	Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of †scleromyositis'. Acta Neuropathologica, 2021, 142, 395-397.	7.7	7
138	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	1.0	7
139	Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 184-192.	0.8	7
140	Patient-provider communication about medication cost in rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 93-100.	2.2	6
141	NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. Journal of Scleroderma and Related Disorders, 2022, 7, 62-70.	1.7	6
142	Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatism, 2021, 51, 983-988.	3.4	6
143	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 53-60.	0.8	6
144	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39, 142-148.	0.8	6

MARIE HUDSON

#	Article	IF	CITATIONS
145	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 1156-1162.	2.0	5
146	Assessment of English–French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. Body Image, 2017, 22, 97-102.	4.3	5
147	Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. Rheumatology, 2020, 59, 820-827.	1.9	5
148	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). Arthritis Research and Therapy, 2020, 22, 132.	3.5	5
149	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. Chest, 2021, 160, 2158-2162.	0.8	5
150	Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research. Journal of Cell Communication and Signaling, 2012, 6, 187-190.	3.4	4
151	Determinants and functional impacts of diaphragmatic involvement in patients with inclusion body myositis. Muscle and Nerve, 2021, 63, 497-505.	2.2	4
152	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	3.4	4
153	Anti-HMGCR antibodies in systemic sclerosis. Medicine (United States), 2016, 95, e5280.	1.0	4
154	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	1.6	4
155	Influenza Vaccine Hesitancy and Its Determinants Among Rheumatology Patients. ACR Open Rheumatology, 2022, 4, 352-362.	2.1	4
156	Measuring the Impact of <scp>MyLupusGuide</scp> in Canada: Results of a Randomized Controlled Study. Arthritis Care and Research, 2023, 75, 529-539.	3.4	4
157	Validity of Self-Reported Comorbidities in Systemic Sclerosis: Table 1 Journal of Rheumatology, 2009, 36, 1477-1480.	2.0	3
158	Rapidly progressive melanoma differentiation–associated protein 5–positive amyopathic dermatomyositis in an HIV-positive patient. JAAD Case Reports, 2017, 3, 158-161.	0.8	3
159	Dermoskeletics to preserve mobility and function in inclusion body myositis. Neurology, 2018, 91, 760-760.	1.1	3
160	A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. Biometrics, 2021, 77, 424-438.	1.4	3
161	Allopurinol and cardiovascular events: Timeâ€related biases in observational studies. Arthritis Care and Research, 2021, , .	3.4	3
162	Risk of rheumatic disease in breast implant users: a qualitative systematic review. Gland Surgery, 2021, 10, 2557-2576.	1.1	3

#	Article	IF	CITATIONS
163	The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 88-94.	0.8	3
164	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	1.2	3
165	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. Rheumatology, 2022, 61, 3401-3407.	1.9	3
166	Novel Approaches to Discovery of Biomarkers in Rheumatoid Arthritis: Comment on the Article by Oswald et al. Arthritis and Rheumatology, 2015, 67, 2276-2277.	5.6	2
167	No Evidence for Depression Screening in Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Journal of Rheumatology, 2016, 43, 992-992.	2.0	2
168	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 57-63.	1.7	2
169	Letter in response to â€~Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors'. European Journal of Cancer, 2019, 112, 47-48.	2.8	2
170	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. Current Treatment Options in Rheumatology, 2019, 5, 272-289.	1.4	2
171	Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis. Journal of Scleroderma and Related Disorders, 2020, 5, 152-158.	1.7	2
172	Sunlight exposure, sunâ€protective behaviour, and antiâ€citrullinated protein antibody positivity: A general populationâ€based study in Quebec, Canada. Arthritis Care and Research, 2020, , .	3.4	2
173	Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. Genes, 2021, 12, 1349.	2.4	2
174	Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group. Journal of the American Academy of Dermatology, 2022, 87, 1095-1097.	1.2	2
175	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 56-60.	0.8	2
176	Reply. Arthritis Care and Research, 2016, 68, 1053-1054.	3.4	1
177	Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts. Best Practice and Research in Clinical Rheumatology, 2016, 30, 1-2.	3.3	1
178	Cutaneous Lymphangiectasia in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 446-446.	5.6	1
179	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. Respiratory Medicine, 2021, 185, 106482.	2.9	1
180	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatology, 2022, 6, 11.	1.6	1

#	Article	IF	CITATIONS
181	Defining anti-synthetase syndrome: a systematic literature review Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.8	1
182	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	1.9	0
183	Trigeminal neuralgia in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2021, 51, 318-323.	3.4	0
184	Reply. Arthritis and Rheumatology, 2021, 73, 2349-2349.	5.6	0
185	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 142-148.	0.8	Ο
186	Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. Seminars in Arthritis and Rheumatism, 2021, , .	3.4	0